TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Dishman Carbogen Amcis Ltd. ( (IN:DCAL) ) is now available.
Dishman Carbogen Amcis Ltd. announced the approval of its un-audited financial results for the second quarter and half-year ending September 30, 2025, during a board meeting held on November 4, 2025. The results, prepared in accordance with SEBI regulations, were accompanied by a limited review report from the company’s statutory auditors, indicating a transparent disclosure of financial performance. Additionally, a certificate on security cover for non-convertible debentures was also provided, reflecting the company’s commitment to regulatory compliance and financial transparency.
More about Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Ltd. operates in the pharmaceutical industry, focusing on the production and development of active pharmaceutical ingredients and intermediates. The company caters to global pharmaceutical markets, providing services and products that support drug development and manufacturing processes.
Average Trading Volume: 21,451
Technical Sentiment Signal: Buy
Current Market Cap: 45.73B INR
See more data about DCAL stock on TipRanks’ Stock Analysis page.